Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Instil Bio (TIL)
NASDAQ:TIL
Holding TIL?
Track your performance easily
TIL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$9.20 - $92.00
Previous CloseN/A
Volume80.17K
Average Volume (3M)104.64K
Market Cap
$139.78M
Enterprise Value$403.02M
Total Cash (Recent Filing)$8.89M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta6.63
Next Earnings
Mar 10, 2025EPS Estimate
-3.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-11.55
Shares Outstanding6,525,887
10 Day Avg. Volume121,433
30 Day Avg. Volume104,644
Standard Deviation0.62
R-Squared0.02
Alpha-0.00669
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)91.66
Price to Cash Flow (P/CF)-1.70
P/FCF Ratio0.00
Enterprise Value/Market Cap2.88
Enterprise Value/Revenue269.94
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-5.99
Forecast
1Y Price Target
$114.00Price Target Upside443.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Instil Bio News
PremiumCompany Announcements
Instil Bio Secures Loan to Refinance Facility
Bulls Say, Bears Say
Bulls Say
Acquisition PotentialInstil Bio is seen as a potential target for acquisition as more players enter the PD-1/L1 x VEGF market.
Market PotentialAnalysts see room for both PD-1 and PD-L1 inhibitors to thrive commercially in the oncology market, indicating potential for SYN-2510.
ValuationRecent acquisitions by major companies highlight a valuation gap for Instil, suggesting it is undervalued.
Bears Say
EarningsA net loss for 3Q24 of $3.54 per share was reported versus an estimated net loss of $3.08 per share.
Market RiskThe stock is characterized as speculative risk, indicating a higher level of uncertainty and potential volatility.
Operational ChallengesThe timeline delay for the U.S. trial is due to CRO contract negotiations and hiring of clinical development employees.
---
TIL FAQ
What was Instil Bio’s price range in the past 12 months?
Instil Bio lowest stock price was $9.20 and its highest was $92.00 in the past 12 months.
What is Instil Bio’s market cap?
Instil Bio’s market cap is $139.78M.
When is Instil Bio’s upcoming earnings report date?
Instil Bio’s upcoming earnings report date is Mar 10, 2025 which is in 47 days.
How were Instil Bio’s earnings last quarter?
Instil Bio released its earnings results on Nov 13, 2024. The company reported -$3.54 earnings per share for the quarter, missing the consensus estimate of -$2.108 by -$1.432.
Is Instil Bio overvalued?
According to Wall Street analysts Instil Bio’s price is currently Undervalued.
Does Instil Bio pay dividends?
Instil Bio does not currently pay dividends.
What is Instil Bio’s EPS estimate?
Instil Bio’s EPS estimate is -3.22.
How many shares outstanding does Instil Bio have?
Instil Bio has 6,525,887 shares outstanding.
What happened to Instil Bio’s price movement after its last earnings report?
Instil Bio reported an EPS of -$3.54 in its last earnings report, missing expectations of -$2.108. Following the earnings report the stock price went down -5.512%.
Which hedge fund is a major shareholder of Instil Bio?
Among the largest hedge funds holding Instil Bio’s share is Perceptive Advisors LLC. It holds Instil Bio’s shares valued at 23M.
---
Instil Bio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$114.00 (443.63% Upside)
$114.00 (443.63% Upside)
Hedge Fund Trend
Increased
By 345.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.9%
Last 30 Days ▲ 19.3%
Last 30 Days ▲ 19.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
132.61%
12-Months-Change
Fundamentals
Return on Equity
-36.63%
Trailing 12-Months
Asset Growth
-19.90%
Trailing 12-Months
Company Description
Instil Bio
Instil Bio Inc is a clinical-stage cell therapy company. It is developing tumor infiltrating lymphocytes for the treatment of cancer.
---
TIL Stock 12 Month Forecast
Average Price Target
$114.00
▲(443.63% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Affimed
―
Fate Therapeutics
―
Kura Oncology
―
Immatics
―
Bluebird Bio
―
Best Analysts Covering TIL
1 Year
1 Year Success Rate
6/17 ratings generated profit
1 Year Average Return
-31.05%
reiterated a buy rating 3 months ago
Copying Jack Allen's trades and holding each position for 1 Year would result in 35.29% of your transactions generating a profit, with an average return of -31.05% per trade.
---